自身免疫性肝素诱导的血小板减少症
自身免疫性肝素诱导的血小板减少症(aHIT)指患者体内存在抗血小板因子4(PF4)-多阴离子抗体,即使无肝素也能强烈激活血小板。其临床综合征包括迟发性HIT、持续性HIT、自发性HIT综合征、磺达肝癸钠相关HIT、肝素冲管诱导的HIT及伴弥散性血管内凝血的严重HIT。标准抗凝治疗可能有效,但APTT调整的抗凝药常失败,建议使用非APTT调整的药物,大剂量静脉免疫球蛋白可中断抗体诱导的血小板活化。
要点
- aHIT血清在无肝素时即可激活血小板,但高浓度肝素(10-100 IU/mL)可抑制此活化。
- aHIT可表现为迟发性、持续性、自发性HIT综合征及磺达肝癸钠相关HIT等。
- 监测治疗反应时系列纤维蛋白、D-二聚体和纤维蛋白原水平可能比血小板计数更有帮助。
核心结论
- aHIT由无肝素依赖性抗PF4-多阴离子抗体引起,标准抗凝治疗可能有效但APTT调整药物常失败,建议使用非APTT调整药物,大剂量静脉免疫球蛋白可快速恢复血小板计数。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- aHIT血清诱导的血小板活化在高肝素浓度(10-100 IU/mL)下被抑制,系列稀释后通常显示肝素依赖性血小板活化。
- aHIT相关临床综合征包括迟发性HIT、持续性HIT、自发性HIT综合征、磺达肝癸钠相关HIT、肝素冲管诱导的HIT及血小板计数<20×10^9/L伴DIC的严重HIT。
- aHIT可持续数周,系列纤维蛋白、D-二聚体和纤维蛋白原水平而非血小板计数可能有助于监测治疗反应。
- 已发表经验显示APTT调整的抗凝药(阿加曲班、比伐卢定)频繁失败,可能因HIT相关DIC时剂量不足(APTT混杂)。
- 新出现的数据表明大剂量静脉免疫球蛋白可中断HIT抗体诱导的血小板活化,导致血小板计数快速恢复。
关键数值与推荐
- 高肝素浓度10-100 IU/mL可抑制aHIT血清诱导的血小板活化。
- 严重HIT定义为血小板计数<20×10^9/L伴DIC。
- 建议非APTT调整的治疗药物如达那肝素、磺达肝癸钠或直接口服抗凝药(利伐沙班或阿哌沙班),尤其用于持续性HIT的长期管理。
临床怎么用
- 对于aHIT,监测治疗反应时可系列检测纤维蛋白、D-二聚体和纤维蛋白原水平而非仅依赖血小板计数。
- 建议使用非APTT调整的药物如达那肝素、磺达肝癸钠或直接口服抗凝药(利伐沙班或阿哌沙班),尤其用于持续性HIT的长期管理。
- 大剂量静脉免疫球蛋白可考虑用于中断HIT抗体诱导的血小板活化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune heparin-induced thrombocytopenia (aHIT) indicates the presence in patients of anti-platelet factor 4 (PF4)-polyanion antibodies that are able to activate platelets strongly even in the absence of heparin (heparin-independent platelet activation). Nevertheless, as seen with serum obtained from patients with otherwise typical heparin-induced thrombocytopenia (HIT), serum-induced platelet activation is inhibited at high heparin concentrations (10-100 IU mL-1 heparin). Furthermore, upon serial dilution, aHIT serum will usually show heparin-dependent platelet activation. Clinical syndromes associated with aHIT include: delayed-onset HIT, persisting HIT, spontaneous HIT syndrome, fondaparinux-associated HIT, heparin 'flush'-induced HIT, and severe HIT (platelet count of < 20 × 109 L-1 ) with associated disseminated intravascular coagulation (DIC). Recent studies have implicated anti-PF4 antibodies that are able to bridge two PF4 tetramers even in the absence of heparin, probably facilitated by non-heparin platelet-associated polyanions (chondroitin sulfate and polyphosphates); nascent PF4-aHIT-IgG complexes recruit additional heparin-dependent HIT antibodies, leading to the formation of large multimolecular immune complexes and marked platelet activation. aHIT can persist for several weeks, and serial fibrin, D-dimer, and fibrinogen levels, rather than the platelet count, may be helpful for monitoring treatment response. Although standard anticoagulant therapy for HIT ought to be effective, published experience indicates frequent failure of activated partial thromboplastin time (APTT)-adjusted anticoagulants (argatroban, bivalirudin), probably because of underdosing in the setting of HIT-associated DIC, known as 'APTT confounding'. Thus, non-APTT-adjusted therapies with drugs such as danaparoid and fondaparinux, or even direct oral anticoagulants, such as rivaroxaban or apixaban, are suggested therapies, especially for long-term management of persisting HIT. In addition, emerging data indicate that high-dose intravenous immunoglobulin can interrupt HIT antibody-induced platelet activation, leading to rapid platelet count recovery.
引用
- Greinacher A, Selleng K, Warkentin TE, et al. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017. PMID: 28846826. doi:10.1111/jth.13813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。